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Abstract
Background: S-Nitrosylation, the reversible post-translational modification of reactive cysteine residues in proteins,
has emerged as an important mechanism by which NO acts as a signaling molecule. We recently demonstrated
that actin is a major S-nitrosylated protein in the spinal cord and suggested that NO directly attenuates dopamine
release from PC12 cells by causing the breakdown of F-actin. However, the occurrence of S-nitrosylation of actin
remained unclarified in animal pain model. Kinetic analysis of S-nitrosylation of actin in the present study was
made by using NO-generating donors. The biotin-switch assay and purification on streptavidin-agarose were
employed for identification of S-nitrosylated actin.
Results: Dopamine release from PC12 cells was markedly attenuated by NOR1 (t1/2 = 1.8 min) and much less by
NOR3 (t1/2 = 30 min), but not by S-nitroso-glutathione, an endogenous NO donor. A membrane-permeable cGMP
analogue could not substitute for NOR1 as a suppressor nor could inhibitors of soluble guanylate cyclase and
cGMP-dependent protein kinase attenuate the suppression. S-Nitrosylated actin was detected by the biotin-switch
assay at 5 min after the addition of NOR1. Consistent with the kinetic analysis, actin in the spinal cord was rapidly
and maximally S-nitrosylated in an inflammatory pain model at 5 min after the injection of 2% formalin into the
hind paws. In vivo patch-clamp recordings of the spinal dorsal horn, NOR3 showed an inhibitory action on
inhibitory synaptic transmission in interneurons of the substantia gelatinosa.
Conclusions: The present study demonstrates that rapid S-nitrosylation of actin occurred in vitro in the presence of
exogenous NO-generating donors and in vivo in inflammatory pain model mice. Our data suggest that, in addition
to the well-known cGMP-dependent protein kinase pathway, S-nitrosylation is involved in pain transmission via
disinhibition of inhibitory neurons.
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patch-clamp recordings
Background
Abundant evidence has demonstrated that activation of
the N-methyl-D-aspartate (NMDA) subtype of glutamate
receptors and subsequent production of nitric oxide
(NO) are key events in neurotransmission and synaptic
plasticity in the central nervous system [1,2]. Different
from many conventional neurotransmitters, NO, a reac-
tive free-radical gas, simply diffuses from the nerve
terminals into adjacent cells as anterograde and retro-
grade messengers and participates in numerous physio-
logical and pathophysiological processes including
nociception and pain hypersensitivity in the spinal cord
[3-6]. We and others have demonstrated that NO con-
tributes to the development and maintenance of hyper-
algesia and allodynia in models of acute and chronic
pain [7-10]. A rapid release of citrulline, a marker of
NO synthesis, is observed in the spinal cord following a
subcutaneous injection of formalin and is associated
w i t hab i p h a s i cf l i n c h i n gb e havior of the injected paw
[11]. On the other hand, spinally administered NO
donors depress ongoing impulse activity of dorsal horn
neurons [12]; and inhibition of spinal NO synthase
(NOS) leads to increased neuronal activity in the dorsal
horn [13]. Thus the involvement of NO in pain is not
consistent and is still controversial, probably due to dif-
ferences in the experimental design and dose and nature
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result from the existence of 2 signaling pathways of NO
action. One is the classical pathway, where NO binds to
the heme group of the soluble guanylyl cyclase (sGC)
and activates it, leading to the generation of a second
messenger, guanosine 3’,5 ’-cyclic monophosphate
(cGMP), and then activation of cGMP-dependent pro-
tein kinase (PKG). The other is protein S-nitrosylation,
i.e., the covalent attachment of a NO group to a reactive
cysteine thiol, which has been recognized as a reversible
post-translational modification [16,17].
Among methods for studying protein S-nitrosylation,
the biotin-switch method has rapidly gained popularity
because of the ease with which it can detect individual
S-nitrosylated proteins in biological samples [18]. Over the
past decade, the S-nitrosylation of more than 100 proteins,
e.g., enzymes, transcription factors, ion channels, and
structural proteins including NMDA receptors [19] and
sGC [20], has directly been implicated in the regulation of
cellular signaling pathways in intact cellular systems, based
on data obtained by use of the biotin-switch method. We
recently demonstrated that actin is a major S-nitrosylated
protein in the mouse spinal cord, as evidenced by incuba-
tion of a spinal cord homogenate with S-nitroso-N-acetyl-
DL-penicillamine (SNAP), an NO donor, and that it is also
S-nitrosylated in PC12 cells [21]. NO decreases the
amount of filamentous actin (F-actin), just like cytochala-
sin B, and attenuates the release of dopamine from PC12
cells. However, the relationship between actin S-nitrosyla-
tion with F-actin breakdown and inhibition of dopamine
release remains unknown. To address this issue, we char-
acterized the effect of NO donors on dopamine release
from PC12 cells, using donors having controlled rates of
NO generation, i.e., (±)-(E)-4-methyl-2-[(E)-hydroxyi-
mino]-5-nitro-6-methoxy-3-hexenamide (NOR1), (±)-(E)-
4-ethyl-2-[(E)-hydroxyimino]-5-nitro-3-hexenamide
( N O R 3 ) ,a n dS N A P ,a sw e l la sS-nitroso-glutathione
(GSNO), an endogenous NO donor [18]. Here we present
that rapid S-nitrosylation of actin occurred in vitro in the
presence of NOR1 and in vivo in the spinal cord of inflam-
matory pain model and correlated with the breakdown of
F-actin and suppression of dopamine release from PC12
cells.
Results
Effect of NO donors on pituitary adenylate cyclase-
activating polypeptide (PACAP)-stimulated dopamine
release from PC12 cells
PACAP is known to stimulate the release of dopamine
from PC12 cells [22]. We recently demonstrated that the
NO donor SNAP inhibits the PACAP-stimulated dopa-
mine release from PC12 cells by causing the S-nitrosylation
of actin [21]. To clarify how S-nitrosylation was involved in
neurotransmitter release, we examined NO donors with
different half-lives, NOR1 (t1/2 =1 . 8m i n ) ,N O R 3( t1/2 =3 0
min), SNAP (t1/2 =6h ) ,a n dG S N O( t1/2 = 10 h), an endo-
genous NO donor, on the PACAP-stimulated dopamine
release from PC12 cells. PC12 cells cultured on 24-well
dishes were pre-incubated for 30 min with 100 μMN O R 1 ,
NOR3, SNAP or GSNO in the presence of 10 μM imipra-
mine, an inhibitor of dopamine reuptake, and then stimu-
lated for 5 min with 10 nM PACAP. Consistent with our
recent findings that PACAP stimulated the release of dopa-
mine, 16.6 ± 0.98% of the total dopamine, in PC12 cells
and that SNAP attenuated it by 26.5%, NOR1 and NOR3
significantly reduced the PACAP-stimulated dopamine
release by 53.2% and 19.4% (Figure 1A). GSNO had almost
no effect on the release. When PC12 cells were stimulated
with 10 nM PACAP in the presence of imipramine, dopa-
mine release occurred in a biphasic manner: rapid release
within 10 min and subsequent gradual release over 60 min
(Figure 1B). When 10 nM PACAP and 100 μMN O R 1
were simultaneously added to PC12 cells, NOR1 inhibited
the first-phase release partially and the second-phase one
completely. Unlike the inhibition by NOR1, the suppressive
effect appeared only after 20-30 min with NOR3 and was
not observed with GSNO (Figure 1B). The first 10-min
release of dopamine was inhibited by NOR1 in a concen-
tration-dependent manner, being 71.2% inhibition at 200
μM, whereas the suppressive effect by NOR3 was weak
even at 200 μM( F i g u r e1 C ) .
To clarify whether the suppressive effect of NO
donors was specific to the PACAP-stimulated release,
next we examined the effect of these NO donors on
KCl-stimulated dopamine release under the same condi-
tions as used for PACAP shown in Figure 1A. After a
30-min preincubation with NO donors in the presence
of imipramine, PC12 cells were incubated for 5 min
w i t h4 5m MK C l .T h ed o p a m i n er e l e a s e db y4 5m M
KCl was 6.91 ± 0.39% of the total cellular dopamine,
smaller than that by 10 nM PACAP. The inhibition pro-
file of KCl-stimulated release by the NO donors was
similar to that for the PACAP-stimulated one; and the
inhibition by NOR1 and NOR3 was 61.4% and 24.8%,
respectively (Figure 1D). These results suggest that NO
inhibited the dopamine release triggered by the 2 agents
by a common mechanism.
Inhibition of formation of F-actin by NO donor
We demonstrated that actin is a major target protein for
S-nitrosylation in PC12 cells and in the spinal cord [21].
To obtain more insight into the relationship between
S-nitrosylated actin and attenuation of dopamine release
by NO donors, we examined the effect of NO donors on
the content and distribution of F-actin in PC12 cells. Since
most of the dopamine release occurred within 10 min
after the addition of PACAP, PC12 cells were treated for
5m i nw i t hv a r i o u sc o n c e n t rations of NOR1 or NOR3;
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Page 2 of 13and the cells were then labeled with Alexa-phalloidin for
F-actin. Whereas actin was broadly distributed in the cells,
F-actin was mainly observed beneath the cell membrane
(Figure 2A). Both NOR1 and NOR3 decreased the fluores-
cence intensity of F-actin (> 40 single cells/experiment,
n = 3) in a concentration-dependent manner from 1 to
100 μM, being decreased maximally to 40-45% of the
initial intensity. However, the concentration of NOR1
necessary for the half-maximal reduction was about 1
order lower than that of NOR3 (Figure 2B). To examine
whether the reduction in F-actin by NO donors was recov-
ered, we examined the fluorescence intensity for 60 min at
1 μM, at which concentration NOR1, but not NOR3, sig-
nificantly decreased it at 5 min after the addition (Figure
2B). The fluorescence intensity of F-actin was significantly
reduced to 76.8% at as early as 5 min after the addition of
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Figure 1 Effect of NO donors on PACAP-stimulated dopamine release from PC 12 cells. A. Inhibition of PACAP-stimulated dopamine
release by NO donors. PC12 cells (4 × 10
5 cells/well) cultured on 24-well dishes were preincubated for 30 min with NOR1, NOR3, SNAP or GSNO
(100 μM concentration of each) and then stimulated with 10 nM PACAP for 5 min in the presence of 10 μM imipramine, an inhibitor of
catecholamine reuptake. Dopamine released into the medium and cellular dopamine were measured by HPLC as described in “Methods.” *P <
0.05; **P < 0.01 vs. without NO donor. B. Time course of inhibition of PACAP-stimulated dopamine release by NO donors. PC12 cells were
stimulated with 10 nM PACAP in the absence and presence of 100 μM NOR1, NOR3 or GSNO, and 10 μM imipramine for the indicated times. *P
< 0.05; **P < 0.01 vs. PACAP alone. C. Concentration dependency of NOR1 and NOR3 for the inhibition of PACAP-stimulated dopamine release
from PC12 cells. PC12 cells were stimulated for 10 min with 10 nM PACAP in the presence of various concentrations of NOR1 or NOR3 and 10
μM imipramine. Released dopamine (mean ± SD, n = 3) was expressed as a percentage of total dopamine (7.2 ± 0.8 ng/well) in PC12 cells. *P <
0.05; **P < 0.01 vs. without NO donor. D. Inhibition by NO donors of the KCl-stimulated dopamine release in PC12 cells. PC12 cells (4 × 10
5 cells/
well) cultured on 24-well dishes were preincubated for 30 min with NOR1, NOR3, SNAP or GSNO (100 μM concentration of each) in the
presence of 10 μM imipramine and then stimulated with 45 mM KCl for 5 min. Dopamine released into the medium (mean ± SD, n = 3) was
measured as described above and expressed as a percentage of total dopamine in PC12 cells. **P < 0.01 vs. without NO donor.
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Page 3 of 131 μM NOR1, and the significant reduction continued up
to 60 min (87.2% of the initial level, Figure 2C). On the
other hand, NOR3 started to show its suppressive effect at
10 min and reached a level of reduction similar to that by
NOR1 at 15 min. These results with NOR1 and NOR3
suggest that F-actin breakdown as well as the suppressive
effect on dopamine release was dependent on NO pro-
duced from NO donors and that the breakdown continued
for 60 min.
No mediation of NO/cGMP/PKG signaling pathway in the
inhibitory effect of NO on dopamine release
To clarify whether the suppressive effect of NOR1 on the
dopamine release was mediated by the NO/cGMP/PKG
signaling pathway, we examined this point by using
agents related to the pathway. Compared to the marked
reduction in dopamine release by 100 μM NOR1, mem-
brane-permeable analogs of cGMP and cAMP, 8-bromo-
cGMP (8-Br-cGMP) and 8-Br-cAMP, did not affect the
PACAP-stimulated dopamine release, regardless of the
presence of 100 μM 3-iso-butyl-1-methylxanthine
(IBMX), a phosphodiesterase inhibitor (Figure 3A). Next
we examined whether the suppressive effect by NOR1
could be attenuated by ODQ or KT5823, an inhibitor of
sGC or PKG, respectively. When PC12 cells were prein-
cubated for 30 min with ODQ (300 nM) or KT5823
(1 μM) in the presence of 100 μM NOR1 and 10 μM imi-
pramine, neither ODQ nor KT5823 attenuated the sup-
pressive effect of PACAP-stimulated dopamine release by
NOR1 (Figure 3B). We further examined whether NOR1
reduced the basal release of dopamine. As with PACAP-
and KCl-stimulated release, NOR1 decreased the basal
release to 42.3%, which release was not affected by
KT5823 or glibenclamide, an ATP-sensitive K
+ channel
blocker [23] (Figure 3C). These results demonstrate that
the suppressive effect of NOR1 was not mediated by the
NO/cGMP/PKG signaling pathway.
Dependency of actin S-nitrosylation by NO donors on NO
generation
To clarify the difference in concentration dependency and
time course of F-actin breakdown between NOR1 and
NOR3, we measured S-nitrosylation of actin in PC12 cells
by performing the biotin-switch assay. S-Nitrosylated actin
BC
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Figure 2 Breakdown of F-actin in PC12 cells by NO donors. A. Representative fluorescent images of F-actin in PC12 cells treated with various
concentrations of NOR1 or NOR3. PC12 cells (3 × 10
4 cells/well) were incubated for 5 min with various concentrations of NOR1 or NOR3. Cells were
fixed with 4% paraformaldehyde, and labeled with Alexa Fluor 488-phalloidin for F-actin. Bar = 5 μM. B, C. Concentration dependency (B) and time
course (C) of F-actin breakdown by NOR1 or NOR3. Fluorescence intensity of more than 40 single cells/dish was quantified by ImageJ as described in
“Methods.” Data are the mean ± SEM of 3 independent experiments. **P < 0.01 vs.0μMN O R 1 ;
#P < 0.05;
##P < 0.01 vs.0μMN O R 3 .
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Page 4 of 13was detected with anti-biotin antibody in NOR1-treated
cells in a donor concentration-dependent manner (data
not shown). When the band intensity of S-nitrosylated
actin was normalized to that of total actin and the ratio
without NO donor treatment was taken as 1, S-nitrosy-
lated actin in PC12 cells rapidly increased 1.27-fold at
5 min after the addition of 300 μMN O R 1a n d1 . 6 4 - f o l da t
60 min. By the treatment of PC12 cells with 300 μM
NOR3, S-nitrosylated actin was 1.66-fold increased at
60 min, comparable to that with NOR1 (1.64-fold, Figure
4A). Similar results on S-nitrosylation were obtained by the
incubation of purified actin with 100 μMN O R 1o rN O R 3 ;
the amount of S-nitrosylated actin rapidly increased 1.29-
to 1.90-fold from 5 min to 30 min with NOR1, but it did
not significantly increase until 30 min with NOR3 (Figure
4B). These results are consistent with the time course of
suppression of the PACAP-stimulated dopamine release
(Figure 1B) and F-actin breakdown (Figure 2C).
In vivo S-nitrosylation of actin in the spinal cord of
inflammatory pain model
Next, we examined whether actin was S-nitrosylated in
vivo in inflammatory pain models. The dorsal spinal cords
at L3-L5 levels were dissected before and 5, 30, 60 min
after 2% formalin injection; and homogenates of them
were prepared. Then the soluble fraction of the homoge-
nates was prepared by a 20-min centrifugation at 100,000
×g .T h ee x t e n to fS-nitrosylation of proteins including
actin was the highest at 5 min and gradually decreased at
30 and 60 min (Figure 5A). To confirm the S-nitrosylation
of actin in vivo, we purified biotinylated proteins from the
soluble fraction of the dorsal spinal cord dissected at
5 min after formalin injection by using a streptavidin-
agarose gel and selectively eluted them with SDS-sample
buffer containing 2-mercaptoethanol. Actin was detected
in the eluate by anti-actin antibody (Figure 5B). However,
S-nitrosylated actin was not detected by the biotin-switch
method in the other inflammatory pain models: 6 and
24 h after injection of carrageenan and complete Freund’s
adjuvant (CFA), respectively (data not shown). These
results demonstrate that S-nitrosylation of actin occurred
rapidly in vivo in the spinal cord of inflammatory pain
model mice.
To confirm this, we tried to detect S-nitrosylated pro-
teins by a more sensitive immunohistochemical method
using anti-nitrosocysteine antibody. We examined whether
the antibody could be used for immunostaining of S-nitro-
sylated proteins in PC12 cells before using the spinal cord.
The immunoreactivity of nitrosocysteine was dense in the
area close to the membrane and co-localized with actin in
PC12 cells (Additional file 1 - Figure S1). The intensity of
immunoreactivity of nitrosocysteine was significantly
increased 1.28- and 1.21-fold by 5-min incubation of PC12
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Figure 3 No mediation of the cGMP/PKG pathway in inhibition
of dopamine release by NOR1. A. Effect of membrane-permeable
cGMP and cAMP analogues on PACAP-stimulated dopamine release.
PC12 cells (4 × 10
5 cells/well) cultured on 24-well dishes were
stimulated for 10 min with 10 nM PACAP and 100 μM NOR1, 8-Br-
cAMP or 8-Br-cGMP in the absence or presence of 100 μM IBMX.
**P < 0.01 vs. none;
##P < 0.01 vs. IBMX. B. Effect of inhibitors of the
cGMP/PKG pathway on PACAP-stimulated dopamine release by
NOR1. PC12 cells were preincubated for 30 min with 100 μM NOR1
and 300 nM ODQ or 1 μM KT5823 in the presence of 10 μM
imipramine. Then the cells were stimulated for 5 min by the
addition of 10 nM PACAP. **P < 0.01 vs. PACAP alone (none). C.
Effect of inhibitors of the cGMP/PKG pathway on basal dopamine
release. PC12 cells were incubated for 5 min with 1 μM KT5823 or 1
μM glibenclamide without or with 100 μM NOR1. Dopamine was
measured by HPLC, and dopamine released into the medium (mean
± SD, n = 3) was expressed as a percentage of total dopamine in
PC12 cells, as described in “Methods.” **P < 0.01 vs. none.
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Page 5 of 13cells with NOR-1 and NOR-3, respectively. These results
demonstrated that S-nitrosylated actin in PC12 cells was
immunostained with anti-nitrosocysteine antibody.
Then we immunostained the spinal cord of inflamma-
tory pain models with the anti-nitrosocysteine antibody.
Transverse sections were prepared from the spinal cords
before and 5 min, 6 h, and 24 h after injection of forma-
lin, carrageenan and CFA, respectively. The immunor-
eactivity of nitrosocysteine was detected in the
superficial layer of the spinal cord (Figure 6A). The
intensity of immunoreactivity was significantly increased
1.29-fold by formalin, but not by carrageenan and CFA
(Figure 6B). Consistent with the results of immunoblot-
ting (Figure 5A), the immunohistochemical studies sup-
port rapid S-nitrosylation of proteins in the spinal cord
in vivo in inflammatory pain model.
Inhibition of inhibitory postsynaptic current (IPSC) in the
spinal cord by NOR3
Finally, we examined NO action on inhibitory synaptic
transmission in the substantia gelatinosa (SG) of the spinal
superficial dorsal horn by using in vivo patch-clamp
recording technique. Stable whole-cell recordings under
voltage-clamp conditions could be obtained from 5 SG
neurons for more than 20 min. SG neurons examined
exhibited spontaneous IPSCs as previously reported [24].
When NOR3 (100 μM) with a longer half-life of 30 min
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Figure 4 S-Nitrosylation of actin by NO donors. A. Time courses of
S-nitrosylation of actin in PC12 cells by NO donors. PC12 cells (7 × 10
5
cells/dish) cultured in 6-cm dishes were exposed to 300 μMN O R 1o r
NOR3 for the indicated times. The cell lysates in HEN buffer were
subjected to the biotin-switch assay as described in “Methods.” Samples
were resolved by non-reducing SDS-PAGE and immunoblotted with
anti-biotin and anti-actin antibodies for S-nitrosylated and total actin,
respectively. Intensity of bands was quantified by using ImageJ. The
extent of S-nitrosylated actin was normalized to total actin, and the
ratio (mean ± SEM, n = 6) of S-nitrosylated actin to total actin at 0 min
was taken as “1.” *P < 0.05; **P < 0.01 vs.0m i nf o rN O R 1 ;
# P<0 . 0 5vs.
0m i nf o rN O R 3 .B.T i m ec o u r s e so fS-nitrosylation of actin by NO
donors. Purified actin (5 μg) was incubated with 100 μMN Od o n o r
NOR1 or NOR3 for the indicated times and subjected to the biotin-
switch assay. *P < 0.05; **P < 0.01 vs.0m i nf o rN O R 1 .
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Figure 5 In vivo S-nitrosylation of actin in the spinal cord of
inflammatory pain model. A.T i m ec o u r s eo fS-nitrosylation of
proteins in the spinal cord. The dorsal spinal cords at the L3-L5 levels
were dissected at 0, 5, 30 or 60 min after injection of 2% formalin (5 μl)
into the hindpaws, and homogenates prepared. The soluble fraction of
the homogenates was subjected to the biotin-switch assay.
S-Nitrosylated and total actin were detected by anti-biotin and anti-
actin antibodies, respectively, as described under “Methods.” An arrow
indicates the position of S-nitrosylated actin (S-NO-actin). B.P u r i f i c a t i o n
of S-nitrosylated actin on streptavidin-agarose. After the soluble
fraction prepared from the dorsal spinal cord at 5 min after formalin
injection was subjected to the biotin-switch method, S-nitrosylated
proteins were purified on streptavidin-agarose. The eluate was
resolved on 10% SDS-PAGE, and S-nitrosylated actin was detected with
anti-actin antibody. Authentic actin (1 μg) was used as a positive
control.
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Page 6 of 13was applied from the surface of the spinal cord for 8-10
min, the spontaneous inhibitory transmission was reduced
as shown in Figure 7A. NOR3 gradually decreased the cur-
rent charge of spontaneous IPSCs and reached a plateau
~8 min after the application (Figure 7B). The spontaneous
inhibitory response (0.62 ± 0.06 of control, n = 5; P <
0.05) was significantly decreased by NOR3. These results
suggest that NO has an inhibitory action on inhibitory
synaptic transmission in the SG.
Discussion
Stimulation of glutamate release by the cGMP/PKG
pathway and inhibition of dopamine release from PC12
cells by S-nitrosylation
NO, a reactive free-radical gas, simply diffuses from the
nerve terminals into adjacent cells as anterograde and ret-
rograde messengers and participates in nociception and
pain hypersensitivity in the spinal cord [3,6]. NO binds to
the heme iron of cGC and initiates the cGMP/PKG path-
way. Based on previous reports indicating that paraformal-
dehyde-resistant NADPH-diaphorase (NADPH-d) activity
is identical to neuronal NOS (nNOS) in the central nervous
system [25,26], we demonstrated earlier that phosphoryla-
tion of NMDA receptor subunit NR2B at its Tyr 1472 and
subsequent nNOS activation are involved in the mainte-
nance of neuropathic pain [27-29]. Furthermore, to eluci-
date biochemical and molecular mechanisms for nNOS
activation in the spinal cord, we established an ex vivo sys-
tem for NADPH-d histochemistry [30], which enabled us
to clarify whether NO itself regulated nNOS activity in situ
by use of NO donors, NOR1, NOR3 and SNAP, with differ-
ent half-lives of 1.8 min, 30 min, and 6 h, respectively [31].
Both NOR1 and NOR3 (100 μM), but not SNAP, enhanced
the cGMP level 10- to 15-fold in isolated spinal cords in the
presence of IBMX. Interestingly, whereas NOR1 slightly
increased nNOS activity assessed by NADPH-d histochem-
istry at 100 μM, NOR3 markedly enhanced it at 10 and 100
μM [31]. We concluded that NO produced by NOR3
enhances nNOS activity mediated by glutamate release
from synaptic terminals and activation of NMDA receptors
via the cGMP/PKG pathway based on the following obser-
vations: (1) The NOR3-enhanced NADPH-d staining is
completely inhibited by NMDA receptors and decreased in
NMDA receptor NR2A knockout mice; (2) ODQ or
KT5823 block the NOR3-enhanced NADPH-d staining;
and (3) conversely, 8-Br-GMP intensely stimulated
NADPH-d staining. In contrast to nNOS activation, the
present study demonstrated that S-nitrosylation of proteins
was rapid and that NOR1 was more effective in inhibiting
dopamine release than NOR3 (Figure 1). Inhibition of
dopamine release by NOR1 was not blocked by ODQ or
KT5823 (Figure 3B). Furthermore, 8-Br-cGMP did not sti-
mulate dopamine release from PC12 cells (Figure 3A).
NOR1 inhibited the basal and 45 mM KCl-evoked dopa-
mine release to a similar extent (Figures 1D and 3C).
Taken together, these results demonstrate that the inhibi-
tion of dopamine release by NOR1 was mediated by
S-nitrosylation, not by the cGMP/PKG pathway.
Correlation of S-nitrosylation with inhibition of dopamine
release and F-actin breakdown
PC12 cells are neurosecretory cells originally established
from a rat pheochromocytoma [32]. PC12 cells synthe-
size and accumulate dopamine, but not noradrenaline or
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Carrageenan CFA
0
0.2
0.4
0.6
0.8
1
1.2
1.4
F
o
l
d
**
B
Figure 6 Nitrosocysteine immunoreactivity in the spinal cord of inflammatory pain models. A. Immunoreactivity of nitrosocysteine in the spinal
cord. Lumbar transverse sections (20 μm) of spinal cords prepared from before and 5 min, 6 h, and 24 h after injection of formalin, carrageenan, and
CFA, respectively, were fixed and stained with anti-nitrosocysteine antibody as described in “Method”.B a r=1 0 0μm. B. Quantification of S-
nitrosocysteine immunostaining. Fluorescence intensity of the spinal cord was quantified by ImageJ. The intensity of the spinal cord in inflammatory
pain models was normalized to that of naive mice, and the intensity (mean ± SEM, n = 23-24) of naive mice was taken as “1.” **P < 0.01.
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Page 7 of 13adrenaline, in sufficient quantity to be measured directly
by HPLC. PACAP-stimulated dopamine release from
PC12 cells was rapid and biphasic (Figure 1B). The inhi-
bition of the release by NOR1 was completely blocked
by 10 min. Since the inhibition by NOR3 was observed
after 20 min, when most of the dopamine stimulated by
PACAP had already been released, the extent of inhibi-
tion by NOR3 and SNAP was much lower as compared
with that by NOR1 (Figure 1A). GSNO is a slow releaser
of NO, as its decomposition rate is just approximately
5% per hour at room temperature. GSNO had no effect
on the PACAP-stimulated dopamine release. In PC12
cells, secretory granules are concentrated close to the
plasma membrane compared with other parts of the
cytoplasm; and the compartmentalization of these gran-
ules is already pronounced under baseline conditions
[33]. The low ability of PC12 cells to compensate for the
release due both to poor synthesizing activity and poor
storage machinery in PC12 cells may explain the time
course of dopamine release from PC12 cells and the
Figure 7 Representative action of NOR3 on inhibitory synaptic transmission in the SG of the spinal dorsal horn in vivo.A . Spontaneous
IPSCs before and 8 min after (left trace) application of NOR3. Two lower consecutive traces of spontaneous IPSCs as shown in an expanded scale
in time. B. Time course of the current charge amplitude of spontaneous IPSCs and relative series resistance of the recording under the action of
NOR3. Data in A and B were obtained from the same neuron. C. Summary showing inhibitory action of NOR3 on inhibitory synaptic response.
*P < 0.05 vs. control.
Lu et al. Molecular Pain 2011, 7:101
http://www.molecularpain.com/content/7/1/101
Page 8 of 13difference in the extent of inhibition among NO donors
(Figure 1). Consistent with the distribution of secretory
granules, F-actin was highly concentrated beneath the
plasma membrane and formed the actin cortex in PC12
cells (Figure 2A). F-actin breakdown by 1 nM NOR1 was
rapid and reached the maximum within 5 min, after
which the breakdown continued for 30 min (Figure 2B).
Increasing concentrations of NOR1 or NOR3 reduced
the content of F-actin at most 60%. The kinetics of inhi-
bition of dopamine releasea n dF - a c t i nb r e a k d o w ni n
PC12 cells by NOR 1 and NOR3 was apparently well cor-
related with the S-nitrosylation of actin (cf. Figures 1, 2,
and 4). The concentration-response curves for these
effects were consistent between NOR1 and NOR3, sug-
gesting that these rapid effects were dependent on the
rate of NO generation from NO donors and were
mediated by S-nitrosylation of actin and other proteins.
However, whereas the decrease in fluorescence intensity
of F-actin was detected at 1 μMN O R 1 ,S-nitrosylated
actin was detected at 100 μM NOR1 by immunoblotting.
This difference may be attributed to the direct labeling of
F-actin by phalloidin and sensitivity for detection. In
addition, NO produced in the medium can easily and
directly reach the F-actin network beneath the plasma
membrane. On the other hand, S-nitrosylated actin was
detected by the biotin-switch method as a small portion
of the total actin in PC12 cells. Since S-nitrosylated actin
was detected in the spinal cord 5 min after the formalin
injection, NO produced in spinal neurons may have
reached the actin network of adjacent neurons/glia and
effectively S-nitrosylated the actin under the conditions
of the in vivo milieu.
Actin filaments are important components of the cell
cytoskeleton, where they are often involved in the pro-
cess of exocytosis. Although the actin of rabbit skeletal
muscle has 5 cysteine residues, at positions 10, 217, 257,
285, and 374, only Cys374 in the C-terminal region is
exposed and important for polymerization [34]; and this
residue is a decisive site of actin for S-nitrosylation [35].
We recently demonstrated that NO is an effective inhi-
bitor of actin polymerization by causing S-nitrosylation
[21]. The maximum reduction in dopamine release from
PC12 cells was around 60% even after a 30-min pre-
incubation of the PC12 cells with NOR1 before PACAP
stimulation, suggesting that factors besides F-actin are
also involved in the dopamine release from PC12 cells.
Dichotomy of NO actions in the spinal cord and
implication in pain
Interestingly, our previous and present studies using NO
donors with different rates of NO generation showed that
NO-enhanced S-nitrosylation of proteins was involved in
the rapid response and that the NO-enhanced phosphory-
lation of proteins is involved in a long-lasting reaction in
cells and tissues, and possibly in vivo in the spinal cord. In
fact, whereas the S-nitrosylation of actin was rapid and
maximal at 5 min after the formalin injection in the inflam-
matory pain model (Figure 5) and immunostaining of
nitrosocysteine in the spinal cord was increased at 5 min
after the formalin injection, but not 6 h after carrageenan
injection and 24 h after CFA injection (Figure 6). On the
other hand, phosphorylation of NR2B at its Tyr1472 and
subsequent nNOS activation were observed 7 days after
the operation in a neuropathic pain model [28,29]. Using a
yeast two-hybrid screening, cysteine-rich protein 4 (CRP4)
has been recently identified as a new effector downstream
of PKG in the nociceptive system [36]. The dichotomy of
NO actions was determined by the expression of proteins
involving the NO/cGMP/PKG pathway. While nNOS is
present in only 1-2% of lumbar dorsal root ganglion (DRG)
neurons, nNOS-containing fibers and small interneurons
are present in all layers of the spinal cord, especially in
lamina II [37]. By contrast, PKGIa is expressed in small- or
medium-diameter neurons of the lumbar dorsal root gang-
lia but is not present in spinal neurons and white matter
tracks [37,38] and the majority of CRP4 mRNA-positive
dorsal root ganglion neurons expressed PKG and periph-
erin [36]. Therefore, NO has been supposed to act as a ret-
rograde messenger, i.e., to diffuse back to the presynaptic
terminals of primary afferent fibers where it stimulates the
release of glutamate via the cGMP/PKG pathway [3,31].
However, whereas CRP4-deficient mice showed no differ-
ence in nociceptive behaviors in acute pain and neuro-
pathic pain, unexpectedly, they became hyperalgesic in
inflammatory pain models as compared with wild-type
mice [36]. In the present study, we demonstrated that actin
was S-nitrosylated in the spinal cord in vivo in inflamma-
tory pain model mice (Figure 5) and that NOR3 decreased
inhibitory synaptic transmission in SG neurons of the dor-
sal horn by in vivo patch-clamp recordings (Figure 7),
suggesting that attenuation of synaptic inhibition by
S-nitrosylation may contribute to the manifestation of
inflammatory pain. In this connection, sodium nitroprus-
side, another NO donor, inhibits ongoing impulse activity
in 49% of all spinal neurons in laminas I and II [12], prob-
ably due to the lack of expression of PKG in these cells.
We recently demonstrated that the nNOS inhibitor
7-nitroindole reduces the accumulation of activated micro-
glia in the superficial layer of neuropathic pain model mice
and blocks the migration of activated microglia in vitro
[39]. Which types of cells possess S-nitrosylated proteins
and whether disinhibition of inhibitory dorsal horn neu-
rons by S-nitrosylation serves as pronociceptive in acute
and chronic pain is an interesting topic in pain research.
Conclusions
S-Nitrosylation has emerged as an important mechanism
by which NO acts as a signaling molecule under
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strates that actin was rapidly S-nitrosylated in vitro by exo-
genous NO-generating donors and in vivo in the spinal
cord of inflammatory pain model mice. NO showed an
inhibitory action on inhibitory synaptic transmission in
the spinal dorsal horn. These findings implicate S-nitrosy-
lation in pain transmission via disinhibition of inhibitory
neurons.
Methods
Materials
SNAP, ODQ, KT5823, and l-carrageenan were obtained
from Wako Pure Chemical (Osaka, Japan). NOR1 and
NOR3 were purchased from Dojindo (Kumamoto,
Japan). GSNO, S-methyl methanethiosulfonate (MMTS),
imipramine hydrochloride, dopamine, 8-Br-cAMP, 8-Br-
cGMP, IBMX, glibenclamide, actin, and CFA were pur-
chased from Sigma-Aldrich (St. Louis, MO, USA).
PACAP and N-[6-(biotinamido)hexyl]-3’-(2’-pyridyl-
dithio)propionamide (biotin-HPDP) were supplied by
Peptide Institute (Osaka, Japan) and Pierce Chemical
(Rockford, IL, USA), respectively. Other chemicals were
of reagent grade.
Measurement of dopamine release from PC12 cells
Pheochromocytoma cell line PC12 cells were maintained
in Dulbecco’s modified Eagle medium supplemented
with 5% fetal calf serum, 10% horse serum, and 50 U/ml
penicillin and kept in a humidified environment of 95%
air and 5% CO2 at 37°C. After PC12 cells had been
seeded in 24-well plates (4 × 10
5 cells/well), they were
cultured for 2 days and then preincubated for 30 min, if
necessary, in 190 μl (or 180 μl) of HEPES buffer (in mM:
NaCl 140, KCl 5, CaCl2 2, MgCl2 1.2, glucose 10, HEPES
10; pH 7.4); and then the appropriate agents (10 μl) were
added once or twice to the medium. Incubation was car-
ried out 37°C for the desired times in the absence or pre-
sence of 10 μM imipramine, an inhibitor of dopamine
reuptake. After incubation, the culture medium in each
well was harvested; and 3% perchloric acid in HEPES buf-
fer was then added to each well for cell lysis. Culture
media and cell lysates were adjusted to pH 4 by the addi-
tion of 1 M sodium acetate, and then the samples were
centrifuged at 15,000 × g for 5 min. The supernatants of
culture media and cell lysates were measured for dopa-
mine released into the medium and cellular dopamine by
using an HPLC column equipped with an Eicom electro-
chemical detector model 700 (Kyoto, Japan). HPLC was
performed by using a reversed-phase C18 column (Eicom
CA-50DS, 2.1 mm × 150 mm) with a phosphate-buffered
mobile phase containing 20% methanol, 50 mg/L EDTA,
and 0.5 mg/L sodium 1-octanesulfonate. The cellular
dopamine content was 7.2 ± 0.8 ng/well; and basal and
PACAP- and KCl-evoked release of dopamine into the
culture medium was 1-1.5, 15-20, and 6-9% of cellular
dopamine, respectively.
S-Nitrosylation of actin and the biotin-switch method
S-Nitrosylated actin was detected by the biotin-switch
method as described previously [16,19]. Briefly, 5 μg puri-
fied actin and 20 μg bovine serum albumin were incubated
in the dark at room temperature with 100 μMN O R 1o r
NOR3 in HEN buffer consisting of 250 mM HEPES (pH
7.7), 1 mM EDTA, and 0.1 mM neocuproine. Then, the
NO donor was removed from the reaction mixture by
cold acetone precipitation; and the pellets were subse-
quently dissolved in HENS buffer containing 25 mM
HEPES (pH 7.7), 0.1 mM EDTA,0 . 0 1m Mn e o c u p r o i n e ,
and 1% sodium dodecyl sulfate (SDS), and blocked with
fresh 4 mM MMTS for 20 min at 50°C. After the samples
had been washed twice by acetone precipitation, the pel-
lets were resuspended in HENS buffer and subjected to
the biotin-switch assay, in which the sample was mixed
with 1 mM ascorbic acid and 0.3 mM biotin-HPDP and
kept for 1 h in the dark. Biotinylated actin was resolved by
non-reducing SDS-polyacrylamide gel electrophoresis
(PAGE), and detected by immunoblotting with peroxi-
dase-conjugated anti-biotin antibody (1:1000; Sigma-
Aldrich). The same membrane was stripped to detect total
actin with anti-actin antibody (1:5000; BD Bioscience, San
Jose, CA, USA) by using Enhanced Chemiluminescence
(Amersham Biosciences, Piscataway, NJ, USA). The inten-
sity of S-nitrosylated actin was quantified by using ImageJ
software and normalized by that of total actin.
For S-nitrosylation of PC12 cells, the cells (7 × 10
5
cells/dish) were cultured on 6-cm dishes for 2 days, and
the medium was replaced with serum-free medium 12 h
prior to experiments. After treatment of the cells with
300 μM NOR1 or NOR3 for the indicated times, the
cells were disrupted by sonication in HEN buffer; and
the lysates were then subjected to the biotin-switch
assay. The samples (30 μg protein/lane) were separated
by non-reducing SDS-PAGE (10% gel) as described
above.
Preparation of inflammatory pain model and
identification of S-nitrosylated actin
Male 5-week-old ddY mice were obtained from SLC
(Hamamatsu, Japan). Mice were housed under conditions
of a 12-h light: 12-h dark cycle, a constant temperature of
22 ± 2°C, and 60 ± 10% humidity. They received food and
water ad libitum. Before and at 5, 30, and 60 min after
injection of 5 μl of 2% formalin into the plantar surface of
both hind paws, the mice were sacrificed; and then their
dorsal spinal cords were removed at L3-L5 levels and
homogenized in HEN buffer. The soluble fraction of the
homogenate was obtained and subjected to the biotin-
switch assay. The samples (20 μg protein/lane) were
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described above.
For purification of S-nitrosylated proteins, the samples
were prepared from dorsal spinal cords at 5 min after 2%
formalin injection. After the biotin-switch assay, free bio-
tin-HPDP was removed by use of an NP-5 column, and
the eluate was incubated overnight at 4°C with 50 μlo fa
streptavidin-agarose slurry. The adsorbed S-nitrosylated
proteins were eluted with SDS-sample buffer at room tem-
perature for 20 min, and the eluate was resolved by 10%
SDS-PAGE. Actin was detected by immunoblotting with
anti-actin antibody. This study was conducted with the
approval of the Animal Care Committee of Kansai Medi-
cal University and carried out in accordance with the ethi-
cal guideline of the Ethics Committee of the International
Association for the Study of Pain.
Fluorescence images for F-actin in PC12 cells
PC12 cells (3 × 10
4 cells/well) were plated on poly-L-
lysine-coated glass-bottomed 35-mm dishes for 2 days.
After the cells had been cultured overnight in serum-free
medium, they were incubated without or with NOR1 or
NOR3 in various concentrations for the desired times.
Alteration of cellular F-actin was examined as reported
previously [19]. Briefly, the cells were rinsed with phos-
phate-buffered saline, fixed with 4% paraformaldehyde in
0.12 M sodium phosphate buffer (pH 7.4) for 10 min,
rinsed with phosphate-buffered saline 3 times, and blocked
with 2% normal goat serum and 1% bovine serum albumin
in phosphate-buffered saline for 30 min. F-actin was
stained with Alexa Fluor 488-phalloidin (1:500, Invitrogen,
Eugene, OR, USA) in phosphate-buffered saline for 2 h at
room temperature. Digital images were captured by a
Zeiss LSM510 laser-scanning confocal microscope (Ober-
kochen, Germany), and the fluorescence intensity was
quantified by using ImageJ. The intensity of more than 40
single cells was quantified at each datum point, and 3
experiments were carried out for each analysis.
Immunohistochemistry
Before and 5 min, 6 h and 24 h after injection of 2% for-
m a l i n ,1 %c a r r a g e e n a n ,a n d1 0μlC F A( 1m g ⁄ml myco-
bacterium in oil) into the plantar surface of both hind
paws, mice were anesthetized and intracardially perfused
with 50 ml of phosphate-buffered saline (PBS) followed
by a fixative containing 4% paraformaldehyde in 0.1 M
sodium phosphate buffer (pH 7.4). Lumbar spinal cords
w e r er e m o v e da n df i x e di n4 %p a r a f o r m a l d e h y d ea n d
0.2% glutaraldehyde in 0.1 M sodium phosphate buffer
(pH 7.4) overnight at 4°C. After immersion in 30% (w/v)
sucrose overnight, spinal cords were embedded in OCT
medium and transverse sections (20-μm thickness) were
cut by a cryostat. Then the sections were washed with
0.2% Triton X-100 in PBS, blocked with 2% normal goat
serum and 1% bovine serum albumin in PBS for 1 h at
room temperature. The sections were processed for
immunohistochemistry with mouse anti-nitrosocysteine
(1:2000, A. G. Scientific, San Diego, CA, USA) overnight
at 4°C as primary antibody. The slides were washed
three times in PBS and incubated with the Alexafluor
546 anti-mouse IgG (1:400; Invitrogen) as the secondary
antibody for 1 h at room temperature. The immuno-
fluorescence was visualized with a Zeiss confocal ima-
ging system LSM510.
Sections (5-6/mouse) of a set of control and experi-
mental spinal cords were concurrently immunostained
and images were captured under the same conditions.
The intensity of immunostaining was quantified by
ImageJ.
Elrectrophysiology
In vivo patch-clamp recordings from spinal dorsal horn
neurons were carried out in normal 6 to 8-week-old rats
essentially as described previously [40,41]. Briefly, under
urethane anesthesia, a thoracolumbar laminectomy was
performed, and then the animal was placed in a stereo-
taxic apparatus. The dura mater was removed, and the
pia-arachnoid membrane was cut to make a window
large enough to allow the patch electrode to enter the
spinal cord. The surface of the exposed area of the
spinal cord was irrigated with Krebs solution (in mM:
NaCl 117, KCl 3.6, CaCl2 2.5, MgCl2 1.2, NaH2PO4 1.2,
glucose 11, NaHCO3 25) equilibrated with 95% O2/5%
CO2. NOR3 were added to the Krebs solution used for
perfusion [41]. The patch pipettes were filled with a Cs
solution (in mM: Cs2SO4 110, tetraethylammonium 5,
CaCl2 0.5, MgCl2 2, EGTA 5, HEPES 5, ATP-Mg 5; pH
7.2). The tip resistance of the patch pipettes was 8-12
MΩ. Series resistance was assessed according to the
response to a 5 mV hyperpolarizing step. This value was
monitored during the recording session, and data were
rejected if values changed by > 15%. The electrode was
advanced into SG (lamina II) of the dorsal horn and
then whole-cell voltage-clamp recording configurations
were blindly performed from SG neurons. IPSCs were
recorded under voltage-clamp conditions at a holding
potential of 0 mV. The current charges of inhibitory
synaptic responses were obtained from spontaneous
IPSCs for 1 s.
Statistics
Data for fluorescence images of F-actin were analyzed
by one-way ANOVA, and statistical significance was
further examined by Dunnett’s test. Data for dopamine
release, S-nitrosylation of actin, and electrophysiology
were analyzed by paired Student’s t-test. Data were pre-
sented as the mean ± SD or the mean ± SEM. P < 0.05
was considered statistically significant.
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Additional file 1: Figure S1 - Validation of anti-nitrosocysteine
antibody for immunostaining of S-nitrosylated proteins in PC12
cells. A-D. Representative fluorescence images of immunostained PC12
cells with anti-nitrosocysteine and actin antibodies. After incubation for 5
min with 100 μM NOR1 (A-C), 100 μM NOR3 or 0.1% DMSO (D), PC12
cells (2 × 10
5 cells/well) were fixed with 4% paraformaldehyde and 0.2%
glutaraldehyde, and labeled with anti-nitrosocysteine/Alexafluora 546-
anti-mouse IgG (red) for S-nitrosylated protein (A, D), and anti-actin
antibody/Alexafluora 488-anti-rabbit IgG (green) for total actin (B).
Double labeling (C) was created by merging the images for
nitrosocystein (A) and actin (B). Immunohistochemistry in PC12 cells was
carried out with anti-nitrosocysteine (1:2000, A.G. Scientific) and anti-actin
(1:50 ZYMED, San Francisco, CA, USA) as described in “Methods”. E.
Negative control without primary anti-nitrosocysteine antibody. Bar = 10
μm. F. Quantification of immunoreactivities in PC12 cells. Fluorescence
intensity was quantified by ImageJ. More than 60 cells were quantified at
each datum point, and 3 experiments were carried out for each analysis.
The nitrosocysteine immunoreactivity was normalized to total actin, and
the ratio (mean ± SEM, n = 3) of DMSO was taken as “1”. **P < 0.01.
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